Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Bagchi, Devika P ^a   Yu, Lihai ^a   Perlmutter, Joel S ^a   Xu, Jinbin ^a   Mach, Robert H ^a   Tu, Zhude ^a   Kotzbauer, Paul T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; IODINE 125; RADIOLIGAND; TAU PROTEIN; IODINE; RADIOPHARMACEUTICAL AGENT;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN HOMOGENATE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIGAND BINDING; MALE; MOUSE; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PROCESS DEVELOPMENT; PROTEIN BINDING; SCREENING TEST; TRANSGENIC MOUSE; ANIMAL; BRAIN; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; METABOLISM; PROCEDURES; RADIOASSAY; SCINTISCANNING;

ALPHA-SYNUCLEIN; ANIMALS; BINDING SITES; BRAIN; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IODINE ISOTOPES; MALE; MICE; MICE, TRANSGENIC; PARKINSON DISEASE; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; TAU PROTEINS;

EID: 84873564460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055031     Document Type: Article

References (44)

1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG, (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23: 837-844.
2. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, et al. (2011) Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 134: 1493-1505.
3. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, et al. (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54: 1916-1921.
4. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K, (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134.
5. Clayton DF, George JM, (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21: 249-254.
6. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90: 11282-11286.
7. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95: 6469-6473.
8. Vilar M, Chou HT, Luhrs T, Maji SK, Riek-Loher D, et al. (2008) The fold of alpha-synuclein fibrils. Proc Natl Acad Sci U S A 105: 8637-8642.
9. Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, et al. (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122: 137-153. 10.1007/s00401-011-0839-6 [doi].
10. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
11. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, et al. (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598-10606.
12. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, et al. (2010) In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74: 77-84.
13. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, et al. (2007) In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27: 10365-10371.
14. Ye L, Velasco A, Fraser G, Beach TG, Sue L, et al. (2008) In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 105: 1428-1437.
15. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, et al. (2011) 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134: 1089-1100. awr038 [pii];10.1093/brain/awr038 [doi].
16. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, et al. (2011) Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 52: 1210-1217. jnumed.111.089730 [pii];10.2967/jnumed.111.089730 [doi].
17. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, et al. (2009) Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 50: 1887-1894.
18. Jensen JR, Cisek K, Funk KE, Naphade S, Schafer KN, et al. (2011) Research towards tau imaging. J Alzheimers Dis 26 Suppl 3: 147-157. V530R7H725703464 [pii];10.3233/JAD-2011-0003 [doi].
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ, (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184.
20. Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, et al. (2005) The AD8: a brief informant interview to detect dementia. Neurology 65: 559-564.
21. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
22. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, et al. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34: 521-533.
23. Hou C, Tu Z, Mach R, Kung HF, Kung MP (2006) Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl Med Biol 33: 203-209. S0969-8051(05)00261-1 [pii];10.1016/j.nucmedbio.2005.10.001 [doi].
24. Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, et al. (1990) The characterization of IBF as a new selective dopamine D-2 receptor imaging agent. J Nucl Med 31: 648-654.
25. Murphy RA, Kung HF, Kung MP, Billings J, (1990) Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents. J Med Chem 33: 171-178.
26. Giasson BI, Uryu K, Trojanowski JQ, Lee VM, (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 274: 7619-7622.
27. Huang C, Ren G, Zhou H, Wang CC, (2005) A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr Purif 42: 173-177.
28. Yu L, Cui J, Padakanti PK, Engel LA, Bagchi DP, et al. (2012) Synthesis and in vitro evaluation of á-synuclein ligands. Bioorg Med Chem in press.
29. Li W, Lee VM, (2006) Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry 45: 15692-15701.
30. Frost B, Jacks RL, Diamond MI, (2009) Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 284: 12845-12852.
31. Jan A, Hartley DM, Lashuel HA (2010) Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research. Nat Protoc 5: 1186-1209. nprot.2010.72 [pii];10.1038/nprot.2010.72 [doi].
32. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, et al. (2004) Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 187: 279-288.
33. Engel LA, Jing Z, O'Brien DE, Sun M, Kotzbauer PT, (2010) Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS ONE 5: e12897.
34. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989. 8948 [pii].
35. Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, et al. (2009) In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol 617: 54-58.
36. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ, (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42: 1142-1146.
37. Jankovic J, Rajput AH, McDermott MP, Perl DP, (2000) The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 57: 369-372.
38. Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, et al. (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127: 2657-2671.
39. Fujishiro H, Ahn TB, Frigerio R, DelleDonne A, Josephs KA, et al. (2008) Glial cytoplasmic inclusions in neurologically normal elderly: prodromal multiple system atrophy? Acta Neuropathol 116: 269-275.
40. Parkkinen L, Hartikainen P, Alafuzoff I, (2007) Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms. Clin Neuropathol 26: 276-283.
41. Wakabayashi K, Mori F, Nishie M, Oyama Y, Kurihara A, et al. (2005) An autopsy case of early ("minimal change") olivopontocerebellar atrophy (multiple system atrophy-cerebellar). Acta Neuropathol 110: 185-190.
42. Gregory A, Westaway SK, Holm IE, Kotzbauer PT, Hogarth P, et al. (2008) Neurodegeneration associated with genetic defects in phospholipase A2. Neurology 71: 1402-1409.
43. Paisan-Ruiz C, Li A, Schneider SA, Holton JL, Johnson R, et al. (2010) Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging.
44. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.